Literature DB >> 25736842

STAT-5 is activated constitutively in T cells, B cells and monocytes from patients with primary Sjögren's syndrome.

M Pertovaara1,2, O Silvennoinen3,4, P Isomäki1,3.   

Abstract

The expression and phosphorylation of signal transducer and activator of transcription-1 (STAT-1) have been shown to be markedly increased in the salivary gland epithelial cells of patients with primary Sjögren's syndrome (pSS). The present aim was to investigate the activation status of different STAT proteins in peripheral blood (PB) lymphocytes and monocytes, and their correlations with clinical parameters in patients with pSS. To this end, PB samples were drawn from 16 patients with active pSS and 16 healthy blood donors, and the phosphorylation of STAT-1, -3, -4, -5 and -6 proteins was studied in T cells, B cells and monocytes using multi-colour flow cytometry. In addition, mRNA expression of STAT molecules in PB mononuclear cells (PBMC) was studied with quantitative reverse transcriptase-polymerase chain reaction (RT-PCR). Basal phosphorylation of STAT-5 was found to be significantly higher in PB T cells, B cells and monocytes in patients with pSS than in healthy controls. The expression of STAT-5 mRNA was not increased in PBMC. pSTAT-5 levels in B cells and monocytes showed a significant correlation with serum immunoglobulin (Ig)G levels and anti-SSB antibody titres. Constitutive STAT-5 activation in monocytes and CD4(+) T cells was associated with purpura. There were no major differences in the activation of other STATs between pSS patients and healthy controls. In conclusion, STAT-5 is activated constitutively in PB leucocytes in patients with pSS, and basal STAT-5 phosphorylation seems to associate with hypergammaglobulinaemia, anti-SSB antibody production and purpura.
© 2015 British Society for Immunology.

Entities:  

Keywords:  ESSDAI; ESSPRI; PBMC; STAT; Sjögren's syndrome; phosphorylation

Mesh:

Substances:

Year:  2015        PMID: 25736842      PMCID: PMC4469153          DOI: 10.1111/cei.12614

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  39 in total

Review 1.  Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group.

Authors:  C Vitali; S Bombardieri; R Jonsson; H M Moutsopoulos; E L Alexander; S E Carsons; T E Daniels; P C Fox; R I Fox; S S Kassan; S R Pillemer; N Talal; M H Weisman
Journal:  Ann Rheum Dis       Date:  2002-06       Impact factor: 19.103

2.  Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation.

Authors:  Yongzhi Cui; Greg Riedlinger; Keiko Miyoshi; Wei Tang; Cuiling Li; Chu-Xia Deng; Gertraud W Robinson; Lothar Hennighausen
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

3.  A longitudinal cohort study of Finnish patients with primary Sjögren's syndrome: clinical, immunological, and epidemiological aspects.

Authors:  M Pertovaara; E Pukkala; P Laippala; A Miettinen; A Pasternack
Journal:  Ann Rheum Dis       Date:  2001-05       Impact factor: 19.103

4.  The activity of JAK-STAT pathways in rheumatoid arthritis: constitutive activation of STAT3 correlates with interleukin 6 levels.

Authors:  Pia Isomäki; Ilkka Junttila; Krista-Liisa Vidqvist; Markku Korpela; Olli Silvennoinen
Journal:  Rheumatology (Oxford)       Date:  2014-11-17       Impact factor: 7.580

Review 5.  Signaling through the hematopoietic cytokine receptors.

Authors:  J N Ihle; B A Witthuhn; F W Quelle; K Yamamoto; O Silvennoinen
Journal:  Annu Rev Immunol       Date:  1995       Impact factor: 28.527

6.  Variant form of STAT4 is associated with primary Sjögren's syndrome.

Authors:  B D Korman; M I Alba; J M Le; I Alevizos; J A Smith; N P Nikolov; D L Kastner; E F Remmers; G G Illei
Journal:  Genes Immun       Date:  2008-02-14       Impact factor: 2.676

7.  Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation.

Authors:  Arian Laurence; Cristina M Tato; Todd S Davidson; Yuka Kanno; Zhi Chen; Zhengju Yao; Rebecca B Blank; Françoise Meylan; Richard Siegel; Lothar Hennighausen; Ethan M Shevach; John J O'shea
Journal:  Immunity       Date:  2007-03       Impact factor: 31.745

8.  Linked T cell receptor and cytokine signaling govern the development of the regulatory T cell repertoire.

Authors:  Matthew A Burchill; Jianying Yang; Kieng B Vang; James J Moon; H Hamlet Chu; Chan-Wang J Lio; Amanda L Vegoe; Chyi-Song Hsieh; Marc K Jenkins; Michael A Farrar
Journal:  Immunity       Date:  2008-01       Impact factor: 31.745

9.  Constitutive STAT3 activation in peripheral CD3(+) cells from patients with primary Sjögren's syndrome.

Authors:  H L Ramos; G Valencia-Pacheco; J Alcocer-Varela
Journal:  Scand J Rheumatol       Date:  2008 Jan-Feb       Impact factor: 3.641

10.  Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study.

Authors:  Serge D Steinfeld; Laure Tant; Gerd R Burmester; Nick K W Teoh; William A Wegener; David M Goldenberg; Olivier Pradier
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

View more
  10 in total

Review 1.  Myeloid Populations in Systemic Autoimmune Diseases.

Authors:  María Morell; Nieves Varela; Concepción Marañón
Journal:  Clin Rev Allergy Immunol       Date:  2017-10       Impact factor: 8.667

Review 2.  Review of autoantigens in Sjögren's syndrome: an update.

Authors:  Louis Tong; Vanessa Koh; Bernard Yu-Hor Thong
Journal:  J Inflamm Res       Date:  2017-08-07

3.  Analysis of Clinical Characteristics of Immune-Related Dry Eye.

Authors:  Hua Wang; Ping-Bao Wang; Ting Chen; Jing Zou; Ya-Jia Li; Xu-Fang Ran; Qiang-Xiang Li
Journal:  J Ophthalmol       Date:  2017-05-30       Impact factor: 1.909

4.  Mapping of Signaling Pathways Linked to sIgAD Reveals Impaired IL-21 Driven STAT3 B-Cell Activation.

Authors:  Andri L Lemarquis; Fannar Theodors; Helga K Einarsdottir; Bjorn R Ludviksson
Journal:  Front Immunol       Date:  2019-03-18       Impact factor: 7.561

5.  Evaluating STAT5 Phosphorylation as a Mean to Assess T Cell Proliferation.

Authors:  Michael Bitar; Andreas Boldt; Marie-Theres Freitag; Bernd Gruhn; Ulrike Köhl; Ulrich Sack
Journal:  Front Immunol       Date:  2019-04-05       Impact factor: 7.561

6.  Single Cell Based Phosphorylation Profiling Identifies Alterations in Toll-Like Receptor 7 and 9 Signaling in Patients With Primary Sjögren's Syndrome.

Authors:  Richard Davies; Irene Sarkar; Daniel Hammenfors; Brith Bergum; Petra Vogelsang; Silje M Solberg; Sonia Gavasso; Johan G Brun; Roland Jonsson; Silke Appel
Journal:  Front Immunol       Date:  2019-02-21       Impact factor: 7.561

7.  Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis In Vivo and Baseline Signaling Profile Associates With Treatment Response.

Authors:  Maaria Palmroth; Krista Kuuliala; Ritva Peltomaa; Anniina Virtanen; Antti Kuuliala; Antti Kurttila; Anna Kinnunen; Marjatta Leirisalo-Repo; Olli Silvennoinen; Pia Isomäki
Journal:  Front Immunol       Date:  2021-09-24       Impact factor: 7.561

8.  Impaired activation of STAT5 upon IL-2 stimulation in Tregs and elevated sIL-2R in Sjögren's syndrome.

Authors:  Magdalena Keindl; Richard Davies; Brith Bergum; Johan G Brun; Daniel Hammenfors; Roland Jonsson; Valeriya Lyssenko; Silke Appel
Journal:  Arthritis Res Ther       Date:  2022-05-07       Impact factor: 5.606

9.  Aberrant signaling of immune cells in Sjögren's syndrome patient subgroups upon interferon stimulation.

Authors:  Irene Sarkar; Richard Davies; Anders K Aarebrot; Silje M Solberg; Aleksandra Petrovic; Anagha M Joshi; Brith Bergum; Johan G Brun; Daniel Hammenfors; Roland Jonsson; Silke Appel
Journal:  Front Immunol       Date:  2022-08-22       Impact factor: 8.786

Review 10.  The Potential Role of Trained Immunity in Autoimmune and Autoinflammatory Disorders.

Authors:  Rob J W Arts; Leo A B Joosten; Mihai G Netea
Journal:  Front Immunol       Date:  2018-02-20       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.